Volume : 09, Issue : 03, March – 2022
Title:
28.REVIEW ON IMPACT OF COVID-19 ON CARDIOVASCULAR DISEASES
Authors :
Mr.Rupesh Jain, 2Deepti, Deependra Singh, Deepesh Rajak, Dilip Ahirwar,
Sheetal Jain
Abstract :
Coronavirus disease 2019 (COVID-19), caused by a strain of coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic that has affected the lives of billions of individuals. Many patients with COVID-19 experience acute myocardial injury, as evident by an increase in cardiac troponin levels. A significant proportion of hospitalized patients, particularly those with severe illness developed heart failure (23%). Potential drug–disease interactions affecting patients with COVID-19 and comorbid cardiovascular diseases are also becoming a serious concern. In this Review, we summarize Coronavirus-2 (SARS-CoV-2), Pre-existing Cardiovascular Disease, and Outcomes in Patients with Cardiovascular Disease, Acute Cardiovascular Injury, Mechanism of Cardiovascular Injury and Management Consideration for Specific Clinical Cardiovascular Scenarios in Patients with Suspected or Confirmed COVID-19.
Key words: COVID-19, Cardiovascular Disease, Management, Outcomes, Review
Cite This Article:
Please cite this article in press Rupesh Jain et al, Review On Impact Of Covid-19 On Cardiovascular Diseases., Indo Am. J. P. Sci, 2022; 09(3),.
Number of Downloads : 10
References:
1. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease Control and prevention. J Am Med Assoc 2020.
2. The world health organization coronavirus disease 2019 (COVID-19) situation report e61. Available at:-, https://www.who.int/docs/default-source/ coronaviruse/situation- reports/20200321-sitrep-61-covid-19.pdf? sfvrsn¼f201f85c_2. [Accessed 22 March 2020].
3. Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med 2020.
4. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020.
5. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. J Am Med Assoc 2020.
6. Wu Q, Zhou L, Sun X, et al. Altered lipid metabolism in recovered SARS patients twelve years after infection. Sci Rep 2017;7:9110.
7. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020.
8. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020.
9. Nicin L, Abplanalp WT, Mellentin H, Kattih B, Tombor L, John D, et al. Cell type specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts. European Heart Journal. 2020.
10. ASE Statement on Point-of-Care Ultrasound (POCUS) During the 2019 Novel Coronavirus Pandemic. Available at: https://www.asecho.org/wp content/uploads/2020/04/POCUS-COVID_FINAL2_web.pdf. Accessed April 20, 2020.
11. Little P. Non-steroidal anti-inflammatory drugs and covid-19. BMJ. 2020;368:m1185.
12. Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial. International journal of antimicrobial agents. 2020:105949-.
13. Mahevas M, Tran V-T, Roumier M, Chabrol A, Paule R, Guillaud C, et al. No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial. medRxiv. 2020:2020.04.10.20060699.
14. Shamshirian A, Hessami A, Heydari K, Alizadeh-Navaei R, Ebrahimzadeh MA, YIP GW, et al. Hydroxychloroquine Versus COVID-19: A Periodic Systematic Review and Meta-Analysis. medRxiv. 2020:2020.04.14.20065276.
15. Lakkireddy DR, Chung MK, Gopinathannair R, Patton KK, Gluckman TJ, Turagam M, et al. Guidance for Cardiac Electrophysiology During the Coronavirus (COVID-19) Pandemic from the Heart Rhythm Society COVID-19 Task Force; Electrophysiology Section of the American College of Cardiology; and the Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology, American Heart Association. Circulation;0(0).
16. Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, et al. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol. 2018;71(16):1755-64.
17. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet. 2020.
18. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA. 2020.
19. Bangalore S, Sharma A, Slotwiner A, Yatskar L, Harari R, Shah B, et al. ST-Segment Elevation in Patients with Covid-19 — A Case Series. New England Journal of Medicine. 2020.
20. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-9.
21. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiology. 2020.
22. COVID-19 drug interactions. Available at: https://www.covid19-druginteractions.org/, Accessed April 20, 2020.
23. Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. The Lancet. 2020.